2 days ago
Future Health GCC Stem Cell Bank launches in-house GMP exosome production facility
Future Health GCC Stem Cell Bank, a recognised leader in stem cell banking and cellular science, has officially launched its new, in-house GMP (Good Manufacturing Practice) exosome production facility at its premises in Dubai Healthcare City. This milestone marks a significant advancement in the company's ongoing efforts to enhance its capabilities in biological processing and life sciences innovation.
The newly developed facility enables Future Health GCC to produce GMP-compliant exosome preparations under strict international quality standards. This infrastructure supports a wide range of scientific and research-focused applications, reinforcing the company's position as a technology-forward organisation in the region.
Exosomes, which are naturally occurring vesicles secreted by cells, are currently being explored globally for their role in intercellular communication and potential applications in research and biotechnology. Future Health GCC's initiative reflects its commitment to supporting this growing area of scientific study.
'The launch of our GMP exosome production facility is a key milestone that showcases our continuous investment in high-standard, advanced technologies,' said Ahmad Al Ahmad, CEO of Future Health GCC Stem Cell Bank. 'With this addition, we are proud to contribute to the development of the region's biotech infrastructure and facilitate future regenerative medicine'
The facility is designed to accommodate scalable exosome production from various cell sources, with processes adhering to international GMP standards. All production batches are handled within tightly controlled environments, and finished products are stored in ultra-low temperature freezers at -80°C, monitored through a cloud-based temperature control system to ensure product consistency and integrity.
The new facility will also enable collaboration opportunities with research institutions, biotech startups, and academic entities seeking reliable, quality-controlled exosome products for non-clinical and investigational use.
